Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Iovance Biotherapeutics Inc (IOVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,040,019
  • Shares Outstanding, K 95,590
  • Annual Sales, $ 0 K
  • Annual Income, $ -92,060 K
  • 36-Month Beta 2.71
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.33
  • Number of Estimates 5
  • High Estimate -0.30
  • Low Estimate -0.36
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +5.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.82 +10.67%
on 10/11/18
13.95 -22.08%
on 09/20/18
-2.83 (-20.66%)
since 09/18/18
3-Month
9.82 +10.67%
on 10/11/18
18.25 -40.44%
on 08/31/18
-3.43 (-23.99%)
since 07/18/18
52-Week
6.60 +64.70%
on 10/24/17
19.90 -45.38%
on 03/13/18
+3.52 (+47.89%)
since 10/18/17

Most Recent Stories

More News
Iovance Biotherapeutics, Inc. Announces Closing of $252 Million Common Stock Public Offering

Offering Includes Exercise in Full of the Underwriter's Option to Purchase an Additional 3.3 Million Shares of Common Stock

IOVA : 10.93 (+0.46%)
Iovance Biotherapeutics Reports Results from FDA End of Phase 2 meeting and Provides Updates About the Company's Clinical Program

--FDA acknowledged acceptability of a single-arm cohort for registration in metastatic melanoma post PD-1 blocking antibody and, if BRAF mutation positive, a BRAF inhibitor or BRAF inhibitor with MEK inhibitor...

IOVA : 10.93 (+0.46%)
Iovance Biotherapeutics to Present at the 2018 Cantor Global Healthcare Conference

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that Timothy Morris,...

IOVA : 10.93 (+0.46%)
Immuno Oncology & Targeted Therapy Companies Set to Breakout

HENDERSON, NV / ACCESSWIRE / September 12, 2018 / Immuno Oncology has been getting investors revved up in 2018. Abpro and Neon announced IPOs and recently, German biotech Affimed agreed to an alliance...

AFMD : 3.20 (-5.04%)
CELG : 82.61 (-1.98%)
IOVA : 10.93 (+0.46%)
Today's Research Reports on Stocks to Watch: Arrowhead Pharmaceuticals and Iovance Biotherapeutics

NEW YORK, NY / ACCESSWIRE / September 7, 2018 / Arrowhead Pharmaceuticals exploded on positive data results on Thursday while shares of Iovance Biotherapeutics were deep in the red on its own concerning...

ARWR : 13.07 (-3.11%)
IOVA : 10.93 (+0.46%)
Are Options Traders Betting on a Big Move in Lion Biotechnologies (IOVA) Stock?

Investors need to pay close attention to Lion Biotechnologies (IOVA) stock based on the movements in the options market lately.

IOVA : 10.93 (+0.46%)
Iovance Biotherapeutics to Present at Two Investor Conferences in September

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management...

IOVA : 10.93 (+0.46%)
Iovance Biotherapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported its second quarter...

IOVA : 10.93 (+0.46%)
Iovance Biotherapeutics Inc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Iovance Biotherapeutics Inc (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern Time....

IOVA : 10.93 (+0.46%)
Iovance Biotherapeutics to Host Second Quarter 2018 Financial Results Conference Call and Webcast on Monday, August 6, 2018

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report...

IOVA : 10.93 (+0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade IOVA with:

Business Summary

Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies...

See More

Key Turning Points

2nd Resistance Point 11.46
1st Resistance Point 11.17
Last Price 10.93
1st Support Level 10.57
2nd Support Level 10.26

See More

52-Week High 19.90
Fibonacci 61.8% 14.82
Fibonacci 50% 13.25
Fibonacci 38.2% 11.68
Last Price 10.93
52-Week Low 6.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar